Champions Oncology (NASDAQ:CSBR) Issues Earnings Results, Beats Expectations By $0.06 EPS

Champions Oncology (NASDAQ:CSBR) posted its quarterly earnings data on Thursday. The biotechnology company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06, FiscalAI reports. The firm had revenue of $15.23 million for the quarter, compared to analyst estimates of $15.04 million. Champions Oncology had a negative return on equity of 26.13% and a negative net margin of 1.82%.

Here are the key takeaways from Champions Oncology’s conference call:

• Revenue and profitability improved: First-quarter revenue rose 9% year over year to $15.2 million, gross margin increased to 50% from 43%, and adjusted EBITDA reached $671,000 versus $59,000 a year ago—marking the fifth consecutive quarter of positive adjusted EBITDA.
• Translational oncology services revenue was $14.3 million, with margins benefiting from lower third-party radiolabeling costs after bringing capabilities in-house and from operating leverage.
• Data licensing momentum accelerated: Data revenue reached $893,000, exceeding the total generated in all of fiscal 2026, supported by a broader customer base and a robust pipeline. Management cautioned that licensing revenue will remain lumpy because contracts close on varying timelines.
• Management remains encouraged by discussions with venture groups and potential pharmaceutical partners regarding Corellia AI, but provided no timing for outside funding or a licensing deal. Any such proceeds could be redirected toward data initiatives, other growth projects, and the bottom line.
• The company used approximately $500,000 of cash during the quarter and ended with $4.4 million of cash and no debt. Sales and marketing expenses rose to $3.0 million from $1.8 million as Champions works to generate returns from its expanded commercial organization.

Champions Oncology Stock Down 2.0%

Shares of CSBR stock opened at $5.00 on Friday. The business has a fifty day simple moving average of $5.40 and a 200 day simple moving average of $5.80. The company has a market cap of $69.54 million, a P/E ratio of -62.45 and a beta of 0.40. Champions Oncology has a twelve month low of $4.83 and a twelve month high of $8.74.

Analyst Ratings Changes

Separately, Weiss Ratings cut Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Champions Oncology has an average rating of “Sell”.

Hedge Funds Weigh In On Champions Oncology

A number of institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in Champions Oncology in the second quarter valued at approximately $103,000. Essex Investment Management Co. LLC acquired a new position in shares of Champions Oncology during the fourth quarter worth $126,000. Jane Street Group LLC bought a new position in shares of Champions Oncology in the 1st quarter valued at $200,000. Goldman Sachs Group Inc. bought a new position in shares of Champions Oncology in the 1st quarter valued at $201,000. Finally, Acadian Asset Management LLC boosted its holdings in shares of Champions Oncology by 28.7% during the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock valued at $341,000 after acquiring an additional 8,814 shares in the last quarter. 41.30% of the stock is currently owned by institutional investors and hedge funds.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.